Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

Back

ESC Professional Premium Access

Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

Session: Renal failure and cardiovascular disease 2

Topic: Renal Failure and Cardiovascular Disease

Speaker: Doctor K. Mahaffey (Stanford, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Kenneth W Mahaffey

Stanford University Medical Center, Stanford (United States of America)

1 presentation

1 follower

5 more presentations in this session

Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial

Speaker: Ms A. Pettersson Meyer (DK)

Access

Abstract

Slides

CAD in kidney transplant recipients: a real-world assessment pre-ISCHEMIA-CKD

Speaker: Doctor B. Rocha (Lisbon, PT)

Access

Abstract

Slides

Epigenetic regulation of miR-181c-5p in a cardiorenal mouse model with co-occurring thrombotic microangiopathy

Speaker: Ms J. Boen (Antwerp, BE)

Access

Abstract

Slides

Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

Speaker: Doctor A. Singh (Boston, US)

Access

Abstract

Slides

The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients

Speaker: Associate Professor W. Wongcharoen (Chiang Mai, TH)

Access

Abstract

Slides

Access the full session

Renal failure and cardiovascular disease 2

Speakers: Doctor K. Mahaffey, Ms A. Pettersson Meyer, Doctor B. Rocha, Ms J. Boen, Doctor A. Singh...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources